METTL2A: A Potential Drug Target and Biomarker (G339175)

Target Name: METTL2A

NCBI ID: G339175

METTL2A

METTL2A: A Potential Drug Target and Biomarker

Methyltransferase-like protein 2A (METTL2A) is a gene that encodes a protein that plays a critical role in the regulation of cellular processes. The protein is involved in the transfer of methyl groups, which are a crucial element in the regulation of gene expression and DNA replication. METTL2A has also been shown to be involved in the development and progression of various diseases, including cancer. As a result, METTL2A has potential as a drug target and biomarker.

The METTL2A gene was first identified in 2007 and has since been shown to encode a protein with 21 amino acid residues. The protein has a molecular weight of 24 kDa and a calculated pI of 6.9. METTL2A is predominantly expressed in the brain and testes and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear envelope (NE) in a variety of cell types.

One of the most significant functions of METTL2A is its role in methylation. Methylation is a process that involves the addition of methyl groups to specific CpG dinucleotide residues in DNA. This modification has a variety of roles in gene expression, including the regulation of gene expression, the regulation of DNA replication, and the regulation of cell division. METTL2A is involved in the transfer of methyl groups from the endoplasmic reticulum to the nuclear envelope, which is the outer membrane of the endoplasmic reticulum. This process is critical for the regulation of nuclear processes and has been implicated in the development and progression of various diseases.

In addition to its role in methylation, METTL2A is also involved in the regulation of cellular processes that are important for the survival and growth of cells. For example, METTL2A has been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together and form tissues. METTL2A has also been shown to play a role in the regulation of cell migration, which is the process by which cells move from one location to another in the body.

METTL2A has also been shown to be involved in the regulation of cellular signaling pathways. For example, METTL2A has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cellular processes that are important for the survival and growth of cells. METTL2A has also been shown to play a role in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of cellular processes that are important for inflammation and stress responses.

In addition to its role in cellular processes, METTL2A has also been shown to be involved in the development and progression of various diseases. For example, METTL2A has been shown to be involved in the development and progression of cancer, including breast cancer and colon cancer. METTL2A has also been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

As a result of its involvement in cellular processes and its potential role in the development and progression of various diseases, METTL2A has significant potential as a drug target and biomarker. Studies have shown that METTL2A can be effectively targeted with small molecules, such as inhibitors, to inhibit its function in cellular processes. In addition, METTL2A has been shown to be involved in several cellular signaling pathways, which makes it an attractive target for drugs that are designed to modulate these pathways.

In conclusion, METTL2A is a gene that encodes a protein that plays a critical role in the regulation of cellular processes. The protein is involved in the transfer of methyl groups, which is crucial for the regulation of gene expression and DNA replication. METTL2A has also been shown to play

Protein Name: Methyltransferase 2A, Methylcytidine

Functions: S-adenosyl-L-methionine-dependent methyltransferase that mediates N(3)-methylcytidine modification of residue 32 of the tRNA anticodon loop of tRNA(Thr)(UGU) and tRNA(Arg)(CCU) (PubMed:28655767, PubMed:34268557). N(3)-methylcytidine methylation by METTL2A requires the N6-threonylcarbamoylation of tRNA (t6A37) by the EKC/KEOPS complex as prerequisite (PubMed:34268557)

The "METTL2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets